Island Pharmaceuticals has begun GMP production of Galidesivir, with the first 5kg batch targeted for an investigational Ebola treatment program in Uganda. A second batch is intended to support a pivotal Marburg animal study under the FDA’s Animal Rule pathway.
- First 5kg GMP batch targeted for completion by end-October 2026
- Supply earmarked for investigational use under the WHO MEURI framework
- Second 5kg batch targeted for completion by late November
- Prospective clinical and virological data may be collected in treated Ebola patients
- Manufacturing supports a planned pivotal Marburg non-human primate study
GMP production moves Galidesivir into physical manufacture
Island Pharmaceuticals Ltd (ASX:ILA) has started physical GMP manufacture of Galidesivir’s active pharmaceutical ingredient, turning a development plan into a two-batch production campaign. Manufacturing began on 1 October at PI Health Sciences, with the first 5kg batch targeted for completion by the end of October.
That initial batch has been earmarked for Island’s approved emergency-use program in Uganda during the ongoing Bundibugyo Ebola outbreak. The proposed use remains investigational and is authorised under the World Health Organization’s Monitored Emergency Use of Unregistered and Investigational Interventions, or MEURI, framework. Island still needs to complete finishing, vialing and packaging before planned shipment to Uganda.
Uganda program could generate prospective human data
The outbreak gives the manufacturing milestone a more immediate purpose than simple inventory building. Island cites WHO data showing 8,137 confirmed cases and 3,926 confirmed deaths as at 27 September 2026, equivalent to a confirmed case fatality ratio of about 48%. The company also says there is no approved specific treatment for Bundibugyo Ebola virus disease.
If treatment proceeds under the prospective MEURI protocol, Island says it may collect clinical, safety and virological data from patients receiving Galidesivir. That could add human evidence to the drug’s existing development record, but the announcement does not provide treatment results, patient numbers or a timetable for any data readout.
Second batch reserved for Marburg Animal Rule work
A second 5kg GMP API batch is targeted for completion by late November 2026. Island intends to use that supply for its broader Ebola strategy and for a planned pivotal Marburg non-human primate study under the US Food and Drug Administration’s Animal Rule pathway.
Island says Galidesivir has benefited from more than US$70 million in prior US government investment, as well as existing human clinical experience and historical efficacy data from non-human primate models of Ebola and Marburg. The manufacturing program also includes analytical method validation, reference-standard preparation and stability studies, establishing the quality framework needed for further development and any potential future government procurement. Those procurement opportunities remain prospective rather than confirmed in this announcement.
Bottom Line?
The next tests are operational: whether both 5kg batches are completed on schedule, whether supply reaches Uganda, and whether the MEURI program produces usable human data alongside progress towards the Marburg animal study.
Questions in the middle?
- Will the first GMP batch be completed, packaged and shipped to Uganda before the Bundibugyo outbreak changes course?
- How many patients could be treated under the MEURI program, and what clinical or virological data will become available?
- Can the second batch support the planned pivotal Marburg study without further manufacturing or development funding requirements?